Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma

Präklinische Studie Zur Etablierung Einer Immuntherapie für Das Nebennierenrindenkarzinom - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. Surgical resection of the tumor is the treatment of choice. However, even after complete resection more than 80 % of patients will experience recurrence of disease. Therefore, new treatment options are urgently needed. This pre-clinical study try to lay the foundations for a successful immunotherapy in patients with ACC.

Inclusion Criteria:

• patients with histological proven adrenocortical carcinoma
• healthy persons as control group
• Life expectancy > 6 months

Exclusion Criteria:

• autoimmune diseases
• severe clinical condition